Physician profile
James Greenberg
NPI 1497859433
$54,090.65
in general payments reported to CMS, 2019-2025
50 companies · $4,767 in 2025
The $4,767 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $11K · 2021: $10K · 2022: $6,812 · 2023: $4,113 · 2024: $4,377 · 2025: $4,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,256.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,573.68 | 2019-2025 | |
| Allergan, INC. | $6,354.69 | 2019-2020 | |
| Novo Nordisk INC | $2,586.67 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Nestle Healthcare Nutrition INC. | $2,102.32 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,029.99 | 2019-2025 | Jardiance |
| Ironwood Pharmaceuticals, INC | $1,879.57 | 2019-2024 | Linzess |
| Lilly USA, LLC | $1,742.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,672.93 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Astrazeneca Pharmaceuticals Lp | $1,515.67 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,508.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,492.46 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,268.09 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $966.83 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $962.23 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $823.07 | 2019-2025 | Trintellix |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.